Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria

Antimicrob Agents Chemother. 1995 Nov;39(11):2585-7. doi: 10.1128/AAC.39.11.2585.

Abstract

LY191145 is the prototype of a series of compounds with activities against vancomycin-resistant enterococci derived by modification of the glycopeptide antibiotic LY264826. LY191145 had MICs for vancomycin- and teicoplanin-resistant enterococci of < or = 4 micrograms/ml for 50% of isolates and < or = 16 micrograms/ml for 90% of isolates. Its MICs for vancomycin-resistant, teicoplanin-susceptible enterococci were 1 to 8 micrograms/ml. LY191145 retains the potent activities of its parent compound against staphylococci and streptococci. In vivo studies in a mouse infection model confirmed these activities. This compound indicates the potential of semisynthetic glycopeptides as agents against antibiotic-resistant gram-positive bacteria.

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacokinetics
  • Anti-Bacterial Agents / pharmacology*
  • Anti-Bacterial Agents / therapeutic use
  • Drug Resistance, Microbial
  • Enterococcus / drug effects*
  • Enterococcus faecalis / drug effects
  • Enterococcus faecium / drug effects
  • Gram-Positive Bacteria / drug effects*
  • Gram-Positive Bacterial Infections / drug therapy
  • Gram-Positive Bacterial Infections / microbiology
  • Humans
  • Male
  • Methicillin Resistance
  • Mice
  • Microbial Sensitivity Tests
  • Rats
  • Rats, Sprague-Dawley
  • Staphylococcus / drug effects
  • Streptococcus / drug effects
  • Vancomycin / analogs & derivatives
  • Vancomycin / pharmacokinetics
  • Vancomycin / pharmacology*
  • Vancomycin / therapeutic use

Substances

  • Anti-Bacterial Agents
  • LY 191145
  • Vancomycin